EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Discovery of telomerase inhibitors: existing strategies and emerging innovations

Lauren Kageler, Elisa Aquilanti iD

Biochemical Society Transactions · 2024

DOI: 10.1042/bst20230264 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biochemical Society Transactions, 2024. Verfasst von Lauren Kageler und 1 weiteren Autor:innen. Beteiligte Einrichtung: Stem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA, U.S.A. Hauptthemen laut MEDLINE: Telomerase, Enzyme Inhibitors, Drug Discovery. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 126 Literaturangaben. Gefördert von: Damon Runyon Physician Scientist Training Award.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Telomerase, crucial for maintaining telomere length, is an attractive target for cancer therapy due to its role in cellular immortality. Despite three decades of research efforts, no small-molecule telomerase inhibitors have been clinically approved, highlighting the extensive challenges in developing effective telomerase-based therapeutics. This review examines conventional and emerging methods to measure telomerase activity and discusses existing inhibitors, including oligonucleotides and small molecules. Furthermore, this review highlights recent breakthroughs in structural studies of telomerase using cryo-electron microscopy, which can facilitate improved structure-based drug design. Altogether, advancements in structural methodologies and high-throughput screening offer promising prospects for telomerase-based cancer therapeutic development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TelomeraseEnzyme InhibitorsDrug DiscoveryHumansCryoelectron MicroscopyNeoplasmsDrug DesignTelomereOligonucleotidesAntineoplastic Agents

Stichwörter der Autor:innen

anti-cancer therapiesdrug discoverytelomerasetelomeres

Substanzen

TelomeraseEnzyme InhibitorsOligonucleotidesAntineoplastic Agents

Autor:innen und Institutionen

  • Stem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA, U.S.A.
  • Division of Neuro Oncology, Dana Farber Cancer Institute, Boston, MA, U.S.A.
  • Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, U.S.A.
  • Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, U.S.A.

ORCID-Profile: Elisa Aquilanti

Förderung

  • Damon Runyon Physician Scientist Training Award

Zitieren

APA

Kageler, L., & Aquilanti, E. (2024). Discovery of telomerase inhibitors: existing strategies and emerging innovations. Biochemical Society Transactions. https://doi.org/10.1042/bst20230264

Vancouver

Kageler L, Aquilanti E. Discovery of telomerase inhibitors: existing strategies and emerging innovations. Biochemical Society Transactions. 2024. doi:10.1042/bst20230264

BibTeX
@article{Kageler2024,
  author = {Kageler, Lauren and Aquilanti, Elisa},
  title = {Discovery of telomerase inhibitors: existing strategies and emerging innovations},
  journal = {Biochemical Society Transactions},
  year = {2024},
  doi = {10.1042/bst20230264}
}
Kostenlos starten →